The Diabetes Prevention Program (DPP), funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and conducted at 25 centers nationwide, was a landmark trial to show that lifestyle changes or metformin can effectively delay diabetes in a diverse population of overweight or obese American adults at high risk of diabetes in the short term and long term compared to placebo.
The public health implications of T2D and the high-risk state of Pre-DM cannot be over-stated, with estimated prevalence of ~25 and ~79 million, respectively. Type 2 diabetes is the main cause of kidney failure, limb amputations, and new onset blindness in adults and a major cause of heart disease and stroke. Type 2 diabetes, which accounts for up to 95 percent of all diabetes cases, becomes more common with increasing age. The prevalence of diagnosed diabetes has more than doubled in the last 30 years, due in large part to the upsurge in obesity.
The goal of DPPOS was to study whether the relatively short-term benefits of delaying diabetes demonstrated in the DPP would translate into long-lasting impact. DPPOS had the following major goals, to determine the effect of DPP interventions on: 1) durability of T2D development; 2) early microvascular disease; and 3) atherosclerosis and CVD risk factors.
For protocol and more details, see About DPP and About DPPOS. For clinical trials.gov information, go to the DPP and DPPOS listings. For study questions, please contact the Coordinating Center here. Click here to read questions and answers about the DPP/DPPOS.
We thank our participants whose commitment and dedication continue to expand our knowledge of diabetes prevention! Your contributions carry on!
The DPPOS Research Group has published over 100 manuscripts with funding support and scientific input from:
NIDDK • NHLBI • NIA • NEI • NCI • ORWH • NICHD • CDC • NIMHD • IHS • ADA
"If you're tipping over into diabetes, you're better off with diet and exercise than you are with medication." -Francis S. Collins, 2010
The biguanide class of antidiabetic drugs, which includes metformin, originates from the French lilac or goat's rue (Galega officinalis), a plant used in folk medicine for several centuries.
April 24, 2015
Congratulations to our DPPOS investigators for their recent ADA achievements:
- David Nathan: First recipient of the ADA Outstanding Achievement in Clinical Diabetes Research Award
- Linda Delahanty: ADA Educator of the Year
- Sam Dagogo-Jack: President, Medicine and Science
- David Marrero: President, Health care and Education
All will be honored at the ADA, and Linda, Sam DJ and David M will give addresses. Congratulations!
Study ("The impact of lifestyle intervention on sedentary time in individuals at high risk of diabetes" by Bonny Rockette-Wagner, et al.) finds each hour spent watching TV daily increases the risk of developing diabetes by 3.4%. Click here to read the Diabetologia press release.
A press release titled "Interventions Lower Diabetes Risk in Women who had Gestational Diabetes" was published by the Endocrine Society. The study, "The Effect of Lifestyle Intervention and Metformin on Preventing or Delaying Diabetes among Women with and without Gestational Diabetes: The Diabetes Prevention Program Outcomes Study 10-Year Follow Up," was published online, ahead of print in The Journal of Clinic Endocrinology and Metabolism. Click here to read the full story.
National Diabetes Education Program releases Guiding Principles for diabetes care. A newly published set of 10 guiding principles highlights areas of agreement for diabetes care that could be clinically useful in diabetes management and prevention. Click here to read the full story.
See the News page for more recent DPP news.
Program Staff Only: To access the research group website, please click here.
DPPOS Coordinating Center